POS0108 EVALUATION OF ORAL BISPHOSPHONATE THERAPY COMPLIANCE

Background:

Osteoporosis is the most frequent bone fragility disease with High risk of fractures by a decrease of bone strength. There is wide range of osteoporosis treatments. Oral bisphosphonates (BP) have been used for years with a good profile of effectiveness and tolerance, but present the main challenge, like the problem of therapeutic compliance.

Objectives:

Assess the degree of compliance of osteoporotic patients on oral BPs with respect to their treatment in order to improve therapeutic adherence.

Methods:

This is a uni-centric descriptive and comparative cross-sectional study conducted in the rheumatology department of the University Hospital in Casablanca among 3 years, from August 2020 to March 2023. The inclusion criteria was any patient followed up in the rheumatology department, at the bone disesas unit, for osteoporosis and treated with oral BP. The exclusion criteria was osteoporotic patients treated with the intravenous bisphosphonate or with other antiosteoporotic medications.

Results:

Were identified 374 patients (368 women and 6 men). sex ratio F/M = 61.3. The mean age was 65.8 years. 66% of patients were treated with alendronic acid (n=247), 12% with ibandronic acid (n=45), and 22% with risedronic acid (n=82). The average length of follow-up was 4.8 years (6 months and 13 years). 85.5% of patients (n=319) took their BP regularly, 14.5% had bad compliance (n=55), 12% were on weekly BP (n=46) and 2.5% on monthly BP (n=9). This was explained by a lack of resources in 9% of cases (n=34): 5% of them were on alendronic acid (n=19), 3% were on risedronic acid (n=11) and 1% were on ibandronic acid (n=4), a lack of understanding in 3. 5% of cases (n=13) who were all on alendronic acid (n=5) or risedronic acid (n=8), product unavailability or side effects in 1% of cases each (n=4) who were on alendronic acid. The side effect described in the cases treated with alendronic acid was digestive discomfort (epigastralgia, nausea) (n=4)

Conclusion:

Adherence to osteoporosis treatment can be poor, because the benefits of osteoporosis treatments are not immediately apparent to patients. According to our study, adherence to oral BP taken monthly was higher than those taken weekly. Adherence to monthly oral BP was satisfactory and superior to weekly oral BP in our study. However, compliance remains suboptimal, and greater attention should be paid to the therapeutic education of these patients being monitored for osteoporosis in order to optimise their management.

REFERENCES:

NIL.

Acknowledgements:

NIL.

Disclosure of Interests:

None declared.